|
 The S&P 500 lost momentum after hitting an all-time intraday high of
1,883.97, with biotechs among the primary decliners. Biogen Idec Inc
<BIIB.O>, down 8.2 percent at $318.53, and Gilead Sciences Inc <GILD.O>,
down 4.6 percent at $72.07, were the two biggest drags on the S&P
500. The Nasdaq biotech index <.NBI> fell 4.4 percent.
U.S. lawmakers have asked Gilead to explain the $84,000 price tag of
its new hepatitis C drug Sovaldi, which is encountering resistance
from health insurers and state Medicaid programs.
"They've been selling them — the techs in particular, as well as the
biotechs, even more particular there. Obviously, it's a momentum
sector, and all the momentum names are getting smacked around," said
Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New
Jersey.
"When you see the momentum names coming out like they are now, that
is telling you they are lightening up here."
Investors continued to monitor geopolitical issues after President
Vladimir Putin signed laws completing Russia's annexation of Crimea.
Russia's MICEX <.MCX> stock index fell 1 percent after a U.S.
decision to slap sanctions on Putin's inner circle.
Nike Inc <NKE.N> fell 5.1 percent to $75.21 and was the heaviest
weight on the Dow after the maker of sports shoes and apparel said
late Thursday that growing pressures from weak emerging market
currencies would take a toll on profit.
The Dow Jones industrial average <.DJI> fell 28.28 points or 0.17
percent, to 16,302.77. The S&P 500 <.SPX> slipped 5.49 points or
0.29 percent, to 1,866.52. The Nasdaq Composite <.IXIC> dropped
42.498 points or 0.98 percent, to close at 4,276.788.
For the week, the Dow rose 1.5 percent, the S&P 500 gained 1.4
percent and the Nasdaq advanced 0.7 percent.
First Solar <FSLR.O> continued its recent meteoric rise, climbing
4.1 percent to $73.37 on Friday, its sixth straight daily increase.
The stock has jumped 38 percent over that period.
Symantec Corp <SYMC.O> tumbled 12.9 percent to $18.20 a day after it
fired Chief Executive Officer Steve Bennett, the second time it has
sacked its top executive in less than two years, raising concerns
about its turnaround efforts.
[to top of second column] |
Despite the market's recent strength, trading volume has been anemic
on positive market days, suggesting limited conviction behind the
move. However, volume received a boost on Friday as options expired
alongside multiple index rebalances. Credit Suisse expected $14
billion in gross trading from the S&P 500 index rebalance, with
another $6 billion from rebalancing in other indexes.
Volume of about 9.6 billion shares traded on U.S. exchanges, well
above the 6.69 billion average so far this month, according to data
from BATS Global Markets.
In earnings news, Tiffany & Co <TIF.N> reported adjusted
fourth-quarter earnings and gave a profit outlook that was below
estimates. Tiffany's stock fell 0.5 percent to $90.73.
Darden Restaurants Inc <DRI.N> reported results largely in line with
expectations and affirmed its plan to divest its Red Lobster
business. Darden's shares rose 2.8 percent to $50.66.
The U.S. Federal Reserve late Thursday said big U.S. banks have
enough capital buffers to withstand a drastic economic downturn. The
central bank said 29 of 30 major banks met the minimum hurdle in its
annual health check.
The only bank to fall under the 5 percent requirement for top-tier
capital was Zions Bancorp <ZION.O>, which said it would resubmit a
capital plan to the Fed. Shares of Zion fell 5.3 percent to $31.24.
Advancing stocks outnumbered declining ones on the New York Stock
Exchange by 1,776 to 1,257. The opposite trend prevailed on the
Nasdaq, where decliners beat advancers by 1,553 to 1,113.
(Editing by Chizu Nomiyama, Nick Zieminski and Jan Paschal)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
